|Boyne CS U19s followed up their first Senior Division 1 North East title with a fantastic win over North Dublin title holders Chanel College Coolock in the Leinster Champions League QF played at the MDL grounds.
| In what turned out to be a hugely competitive game that saw both teams field schoolboy international players, the Trim lads deservedly came out on top with a 4 – 1 victory.
Boyne CS got off to the perfect start when Oisin Devlin converted a penalty after 5 minutes. Boyne CS continued to play high tempo football which saw both sides put bodies on the line in a frantic first half which was full of quality. The second came courtesy of an in-direct free kick from inside the box which Oisin Devlin finished to the top corner leaving the Chanel keeper with no chance.
Chanel started the second half on the front foot and got themselves back in the game shortly after the break making it 2-1. Boyne battled well to withstand the pressure with Captain Cian Lee marshaling the defense brilliantly throughout. The third goal came after a great break down the right from Cian O Hare which saw him find Oisin who managed to dribble the ball past 2 defenders and the goalkeeper to walk into an empty net for his hat trick. Chanel still posed a threat but a superbly taken fourth from Kian Malone, who drilled a low finish into the bottom corner to finish off the North Dublin champions.
They now go on to play Birr in the Leinster semi final in the hunt for a first Leinster Senior Division 1 Title for the school.
|Team – Malachy Doyle, Cian O Hare, Kian Malone, Luke Mahon, Cian Lee (c), Conor Hallinan, Conor Quigley, Luke Byrne, James Clarke, Dylan Farrell and Oisin Devlin. Sub, Aonghus Shortt.
These effects are enhanced by halogenated anesthetics. Instead, your doctor may tell you to take 50 mg per kg (22. There was no official record of my home country ever existing, but there was something similar www.sayadlia24.com. Patients should be informed that a registry for MPS I patients has been established in order to better understand the MPS I disease and to tract clinical outcomes of patients with MPS I over time.